Business Wire

CO-SPATIAL-CORP

30.4.2024 09:01:33 CEST | Business Wire | Press release

Share
Spatial Announces Release 2024 1.0.1

Spatial Corp, the leading software development toolkit provider for design, manufacturing, and engineering solutions and Dassault Systèmes subsidiary, announces the production release of 2024 1.0.1.

Data Prep Is Officially Released

Open New Horizons in Data Import

After launching the alpha version, Data Prep, Spatial’s newest add-on product for 3D InterOp, is officially released to all customers. Supported strategies include filtering small bodies from a model, removing small holes and fillets, and generating an assembly structure from a part with duplicate bodies.

Over the past three months, customer interest confirms the market need for tools to simplify and optimize data during import. Spatial plans to invest further in Data Prep strategies. Functionality releasing soon includes:

  • Capabilities to reduce data to manage while preserving relevant features - to shorten model preparation times for multi-physics and process simulation workflows.
  • Ability to convert polyline data to continuous curves during file restore - to decrease memory consumption and allow for successful import.
  • Option to avoid model shrinkage due to Data Prep strategies like feature removal - to ensure accuracy of collision detection analyses.

Users interested in defining future strategies for Data Prep should contact their account manager.

3D InterOp Extends Support for BIM and Manufacturing

New Support for Navisworks and Writing DXF/DWG Drawing Sheets

The latest release allows BIM customers to read Navisworks files and write drawing sheets in a DXF/DWG format. Additionally, 3D InterOp offers expanded support for the Linux platform in Parasolid-based 3D InterOp.

Point and Table Patterns from Creo Files

Manufacturing relies on hole pattern metadata for automated machining processes such as drilling, milling, cutting, or punching. The latest release of 3D InterOp supports Point and Table type hole patterns in Creo Reader.

Enabling Support of More Formats through External Partners

Extensible 3D InterOp enables partners to create readers and writers for unsupported file formats. These external implementations integrate with existing formats to seamlessly exchange BREP and Visualization data. Customers wishing to develop custom readers and writers can reach out to their account manager for assistance.

Package Size Optimization

For customers not needing support for all bundled formats, ACIS-based 3D InterOp offers guidance on configuring a minimal library set for popular CAD and exchange formats. This minimizes the libraries shipped with their application, saving end-user disk space. For example, supporting only IGES + STEP formats reduces installed library size by 70%.

3D ACIS Modeler Improves Polyhedral Modeling

Polyhedral Sheet Thickening

Additive manufacturing or EDA workflows often start with input that is a 2D representation of a thin part to be processed. When printing or simulating the part, generating a realistic 3D model representing the object with its actual thickness is helpful. This release delivers an API to generate a thickened body from polyhedral sheets.

New Polyhedral Boolean Operations

ACIS now provides functionality to compute the intersection graph between two polyhedral bodies. It also allows combining disjointed polyhedral bodies into a single body, increasing the efficiency of downstream operations.

CGM Provides More Manufacturing Automation and Simulation Tools

Enhancements to Feature Recognition and Removal

Users can now specify an industry context to customize the behavior of feature recognition. Setting the industry context tailors feature recognition to provide intuitive results for applications as diverse as Body-in-White, Micro-Mechanics, and Civil Engineering. This release also offers functionality to remove chamfers.

Improved Polyhedral Modeling for Additive Manufacturing

This release provides various robustness and performance enhancements targeting polyhedral healing and offset. For both types of operations, options are now available to tune the performance for specific configurations.

New Medial Axis Extraction Operator

Simulation engineers need tools to simplify the geometry of parts to reduce analysis computation time. This release features the beta version of the Neutral Fiber Operator, which reduces radially symmetric 3D bodies to a one-dimensional line.

CSM/CVM: Improvements to Cartesian Core Workflows

CVM generates Cartesian elements for interior meshing, resulting in accurate triangular surface meshes and predominantly hexahedral volume meshes. Users can now control the size of these elements, which were previously determined automatically based on surface mesh element size.

About Spatial Corp.

Spatial Corp, a Dassault Systèmes subsidiary, is the leading provider of 3D software development toolkits for technical applications across a broad range of industries. Spatial 3D modeling, 3D visualization, and CAD translation software development toolkits help application developers deliver market-leading products, maintain focus on core competencies, and reduce time-to-market. For over 35 years, Spatial’s 3D software development toolkits have been adopted by many of the world’s most recognized software developers, manufacturers, research institutes, and universities. Headquartered in Broomfield, Colorado, Spatial has offices in the USA, Germany, Japan, China, and the United Kingdom. For more information, visit www.spatial.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240430297301/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye